NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the ...
Johnson & Johnson remains a buy as business momentum accelerates, with Q4 revenue up 9.1% YoY and strong U.S. sales resilience. Their deal with the Trump Administration eliminates tariffs in exchange ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results